The FDA has approved a new Alzheimer’s drug for the first time in almost 20 years. The hope is it would treat the more than 6 million Americans living with Alzheimer’s disease. But the effectiveness of the drug is up for question.

Plus, the Biden administration’s split stance on Puerto Ricans and benefits.

And, the upside to online concerts.

Guests: Jose Delgado, Washington correspondent of El Nuevo Dia and Axios' Bob Herman, and Erica Pandey.
Credits: Axios Today is produced in partnership with Pushkin Industries. The team includes Niala Boodhoo, Sara Kehaulani Goo, Dan Bobkoff, Alexandra Botti, Nuria Marquez Martinez, Sabeena Singhani, and Alex Sugiura. Music is composed by Evan Viola. You can reach us at podcasts@axios.com.
Go deeper:

FDA approves Biogen's Alzheimer's drug despite lack of evidence

The future of concerts is hybrid


Learn more about your ad choices. Visit megaphone.fm/adchoices